Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06152042 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by Biomea Fusion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT06152042 is a Phase 2 study that was terminated before completion, run by Biomea Fusion. The registered enrollment target is 37 participants.
The verdict
NCT06152042, a Phase 2 study, was terminated before completion, sponsored by Biomea Fusion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
Interventions
- DRUG BMF-219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2025-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06152042
The ClinicalTrials.gov registry entry for NCT06152042 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomea Fusion, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMF-219 is the first listed.
NCT06152042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06152042 about?
NCT06152042 is a clinical study titled "Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus". Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
What is the current status of trial NCT06152042?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2023-12-28. Estimated completion is 2025-07-18.
What interventions are being tested in trial NCT06152042?
The interventions under investigation include: BMF-219 (DRUG).
Who is sponsoring clinical trial NCT06152042?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.